{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:26:07Z","timestamp":1785795967339,"version":"3.56.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013279","name":"National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2018ZX09711002"],"award-info":[{"award-number":["2018ZX09711002"]}],"id":[{"id":"10.13039\/501100013279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81825020"],"award-info":[{"award-number":["81825020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803437"],"award-info":[{"award-number":["81803437"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2016YFA0502304"],"award-info":[{"award-number":["2016YFA0502304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFD0200505"],"award-info":[{"award-number":["2017YFD0200505"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.apsb.2020.10.008","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:39:00Z","timestamp":1602718740000},"page":"795-809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"11","author":[{"given":"Fanxun","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-237X","authenticated-orcid":false,"given":"Shiliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guantian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.10.008_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2020.10.008_bib2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European League against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.apsb.2020.10.008_bib3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.10.008_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.apsb.2020.10.008_bib5","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.apsb.2020.10.008_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1473925","article-title":"Mental health and rheumatoid arthritis: toward understanding the emotional status of people with chronic disease","volume":"2019","author":"Ziarko","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.apsb.2020.10.008_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2017.07.019","article-title":"Biomarkers as a treatment guide in rheumatoid arthritis","volume":"186","author":"Takeuchi","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.apsb.2020.10.008_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/RHU.0000000000000788","article-title":"Coffee and tea consumption in relation to risk of rheumatoid arthritis in the women's health initiative observational cohort","volume":"25","author":"Lamichhane","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.apsb.2020.10.008_bib9","first-page":"520","article-title":"Treatment models for rheumatoid arthritis\u2014a review","volume":"8","author":"Abhishek","year":"2016","journal-title":"J Pharmaceut Sci Res"},{"key":"10.1016\/j.apsb.2020.10.008_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000493390","article-title":"Rheumatoid arthritis: a brief overview of the treatment","volume":"27","author":"Bullock","year":"2018","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.apsb.2020.10.008_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrrheum.2009.182","article-title":"Treatment of rheumatoid arthritis: state of the art 2009","volume":"5","author":"van Vollenhoven","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.apsb.2020.10.008_bib12","first-page":"1","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.apsb.2020.10.008_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.apsb.2020.10.008_bib14","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases: miniperspective","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/jm500305p","article-title":"Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis","volume":"58","author":"Lou","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2174\/138955711797247707","article-title":"Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors","volume":"11","author":"Vyas","year":"2011","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib17","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0969-2126(02)00831-6","article-title":"E. coli Dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases","volume":"10","author":"N\u00f8rager","year":"2002","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2020.10.008_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0304-4165(94)00158-T","article-title":"Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite","volume":"1243","author":"Krungkrai","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2020.10.008_bib19","doi-asserted-by":"crossref","first-page":"7990","DOI":"10.1021\/bi000630d","article-title":"Role of Lys 100 in human dihydroorotate dehydrogenase: mutagenesis studies and chemical rescue by external amines","volume":"39","author":"Jiang","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2020.10.008_bib20","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1021\/jm301848w","article-title":"On dihydroorotate dehydrogenases and their inhibitors and uses","volume":"56","author":"Munier-Lehmann","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2005.07.003","article-title":"Pyrimidine pathways in health and disease","volume":"11","author":"L\u00f6ffler","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2020.10.008_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7852","article-title":"Identification of DHODH as a therapeutic target in small cell lung cancer","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2020.10.008_bib23","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","article-title":"The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies","volume":"33","author":"Christian","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2020.10.008_bib24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/11316650-000000000-00000","article-title":"Benefit-risk assessment of leflunomide","volume":"32","author":"Alcorn","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.apsb.2020.10.008_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature09882","article-title":"DHODH modulates transcriptional elongation in the neural crest and melanoma","volume":"471","author":"White","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.10.008_bib26","first-page":"289","article-title":"Leflunomide and malononitrilamides","volume":"313","author":"Silva","year":"1997","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.apsb.2020.10.008_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-065X.1993.tb00654.x","article-title":"The development of brequinar as an immunosuppressive drug for transplantation","volume":"136","author":"Makowka","year":"1993","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2020.10.008_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00685878","article-title":"Multicenter phase II study of brequinar sodium in patients with advanced lung cancer","volume":"32","author":"Maroun","year":"1993","journal-title":"Canc Chemother Pharmacol"},{"key":"10.1016\/j.apsb.2020.10.008_bib29","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1681\/ASN.V1061366","article-title":"Newer immunosuppressive drugs: a review","volume":"10","author":"Gummert","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2020.10.008_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40263-015-0299-y","article-title":"Teriflunomide in patients with relapsing\u2013remitting forms of multiple sclerosis","volume":"30","author":"Chan","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.apsb.2020.10.008_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00002512-200926040-00001","article-title":"Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis","volume":"26","author":"D\u00edaz-Borj\u00f3n","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.apsb.2020.10.008_bib32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00000421-199312000-00014","article-title":"Multicenter phase II study of brequinar sodium in patients with advanced breast cancer","volume":"16","author":"Cody","year":"1993","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.apsb.2020.10.008_bib33","first-page":"5563","article-title":"Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2\u2032-fluoro-1,1\u2032-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt], against experimental tumors","volume":"45","author":"Dexter","year":"1985","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.10.008_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00007890-199202010-00009","article-title":"The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat","volume":"53","author":"Cramer","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.apsb.2020.10.008_bib35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.crohns.2012.09.016","article-title":"Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study","volume":"7","author":"Herrlinger","year":"2013","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1016\/j.apsb.2020.10.008_bib36","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/TP.0b013e31824fd861","article-title":"Immunosuppression with 4SC-101, a novel inhibitor of dihydroorotate dehydrogenase, in a rat model of renal transplantation","volume":"93","author":"Rusai","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.apsb.2020.10.008_bib37","doi-asserted-by":"crossref","first-page":"102129","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis","volume":"43","author":"Muehler","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.apsb.2020.10.008_bib38","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.112.192203","article-title":"Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action","volume":"342","author":"Fitzpatrick","year":"2012","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2020.10.008_bib39","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2353\/ajpath.2010.091227","article-title":"4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas) lpr mice","volume":"176","author":"Kulkarni","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2020.10.008_bib40","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/ibd.21264","article-title":"4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease","volume":"16","author":"Fitzpatrick","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.apsb.2020.10.008_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.10.008_bib42","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1021\/jm300630p","article-title":"Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening","volume":"55","author":"Diao","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib43","doi-asserted-by":"crossref","first-page":"14836","DOI":"10.1038\/srep14836","article-title":"Rational design of benzylidenehydrazinyl-substituted thiazole derivatives as potent inhibitors of human dihydroorotate dehydrogenase with in\u00a0vivo anti-arthritic activity","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2020.10.008_bib44","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/jm501127s","article-title":"Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase","volume":"58","author":"Zhu","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib45","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1039\/C6MD00179C","article-title":"Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents","volume":"7","author":"Song","year":"2016","journal-title":"MedChemComm"},{"key":"10.1016\/j.apsb.2020.10.008_bib46","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1021\/acs.jmedchem.7b01862","article-title":"Design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase","volume":"61","author":"Madak","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib47","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1021\/acs.jmedchem.8b00373","article-title":"Targeting myeloid differentiation using potent 2-hydroxypyrazolo [1,5-a] pyridine scaffold-based human dihydroorotate dehydrogenase inhibitors","volume":"61","author":"Sainas","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.008_bib48","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1574892812666171108124218","article-title":"Use of human dihydroorotate dehydrogenase (hDHODH) inhibitors in autoimmune diseases and new perspectives in cancer therapy","volume":"13","author":"Lolli","year":"2018","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"key":"10.1016\/j.apsb.2020.10.008_bib49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.apsb.2020.10.008_bib50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","article-title":"Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer","volume":"7","author":"Brown","year":"2017","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.10.008_bib51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/2159-8290.CD-16-0612","article-title":"PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition","volume":"7","author":"Mathur","year":"2017","journal-title":"Canc Discov"},{"key":"10.1016\/j.apsb.2020.10.008_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chembiol.2018.03.005","article-title":"Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers","volume":"25","author":"Koundinya","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2020.10.008_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2018.10.014","article-title":"Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells","volume":"29","author":"Bajzikova","year":"2019","journal-title":"Cell Metabol"},{"key":"10.1016\/j.apsb.2020.10.008_bib54","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1016\/j.celrep.2018.05.060","article-title":"Energy metabolism rewiring precedes UVB-induced primary skin tumor formation","volume":"23","author":"Hosseini","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2020.10.008_bib55","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s11255-019-02255-6","article-title":"Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis","volume":"51","author":"Yi","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.apsb.2020.10.008_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0969-2126(00)00077-0","article-title":"Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents","volume":"8","author":"Liu","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2020.10.008_bib57","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/cmdc.200900454","article-title":"Inhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selection","volume":"5","author":"Fritzson","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2020.10.008_bib58","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1039\/C7MD00081B","article-title":"Synthesis, structure\u2013activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase","volume":"8","author":"Zeng","year":"2017","journal-title":"MedChemComm"},{"key":"10.1016\/j.apsb.2020.10.008_bib59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bmcl.2005.09.045","article-title":"The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"16","author":"Heikkila","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2020.10.008_bib60","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nprot.2007.173","article-title":"Collagen-induced arthritis","volume":"2","author":"Brand","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2020.10.008_bib61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jep.2012.11.010","article-title":"Rapid-resolution liquid chromatography TOF-MS for urine metabolomic analysis of collagen-induced arthritis in rats and its applications","volume":"145","author":"Yue","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.apsb.2020.10.008_bib62","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jnutbio.2014.07.006","article-title":"Anti-inflammatory and joint protective effects of extra-virgin olive-oil polyphenol extract in experimental arthritis","volume":"25","author":"Rosillo","year":"2014","journal-title":"J Nutr Biochem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520307590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520307590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:44:44Z","timestamp":1761929084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383520307590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2211383520307590"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.10.008","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}